Abstract
Compelling experimental evidences point to monitoring of the absolute number of circulating ICOS-positive T cells as an early predictive marker of clinical activity of anti-CTLA-4 antibodies in cancer patients. Here, we report available data focusing on this issue and operative procedures to detect ICOS expression on circulating peripheral blood mononuclear cells during CTLA-4 blockade therapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517–2526
Hodi FS, O'Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 311:711–723
Wolckok JD, Hoos A, O’Day S et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412–7420
Weber JS, Dummer R, de Pril V et al (2013) Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 119:1675–1682
Wang W, Daohai Y, Amod AS et al (2012) Biomarkers on melanoma patient T cell associated with ipilimumab treatment. J Transl Med 10:146
Yuan J, Page DB, Ku GY et al (2010) Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor response to ipilimumab therapy. Cancer Immun 10:1
Delyon J, Mateus C, Lefeuvre D et al (2013) Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol 24:1697–1703
Bauquet AT, Jin H, Paterson AM et al (2009) The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells. Nat Immunol 10:167–175
Fu T, He Q, Sharma P et al (2011) The ICOS/ICOSL pathway is required for optimal antitumor response mediated by anti-CTLA-4 therapy. Cancer Res 71:5445–5451
Carthon BJ, Wolchock JD, Yuan J et al (2010) Preoperative CTLA-4 blockade: tolerability and immunomonitoring in the setting of a presurgical clinical trial. Clin Cancer Res 16:2861–2871
Di Giacomo AM, Calabrò L, Danielli R et al (2013) Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. Cancer Immunol Immunother 62:1021–1028
Ribas A, Hanson DC, Noe DA et al (2007) Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist 12:873–883
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Danielli, R. et al. (2016). ICOS Expression as Immunologic Marker in Immune Activating Monoclonal Antibodies. In: Bondanza, A., Casucci, M. (eds) Tumor Immunology. Methods in Molecular Biology, vol 1393. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3338-9_13
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3338-9_13
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3336-5
Online ISBN: 978-1-4939-3338-9
eBook Packages: Springer Protocols